SRB
Sailesh Raj BhanFund Manager Since 1 Apr 2005
EquitySector - Healthcare
Nippon India Pharma Fund - Direct Plan - Growth Plan
3Y Annualised
25.26%
-0.43% 1D
Fund Performance
Fund Multiplier
Fund Info
Peer Comparison
Fund Managers
AMC Details
Performance
1M Returns
5.79%
-0.43% 1D
Benchmark
N/A
Fund Multiplier
Time it would have taken to make your money double (2x), quadruple (4x) and quintuple (5x)
This Fund
3 years 1 months
NIFTY 50
5 years 4 months
FD
9 years 7 months
Fund info
Fund size
₹7875.40 Cr
Min. SIP amount
₹100
Min. Lumpsum amount
₹5000
Exit load
0.01%
1% if redeemed or switched out on or before completion of 1 month from the date of allotment of units. Nil, thereafter.
Risk Profile
Very High Risk
Peer Comparison
This Fund's Performance Compared With Peers
Over the Period of oneMonth
1st
Mirae Asset Healthcare Fund Direct Payout of Income Distribution cum capital withdrawal
8.41%
2nd
Mirae Asset Healthcare Fund Direct Reinvestment of Income Distribution cum capital withdrawal
8.41%
3rd
Mirae Asset Healthcare Fund Direct Growth
8.40%
4th
Mirae Asset Healthcare Fund Regular Payout of Income Distribution cum capital withdrawal
8.28%
5th
Mirae Asset Healthcare Fund Regular Reinvestment of Income Distribution cum capital withdrawal
8.28%
50th
Nippon India Pharma Fund - Direct Plan - Growth Plan
5.79%
Fund Managers
KD
Kinjal DesaiFund Manager Since 25 May 2018
About Nippon India Pharma Fund - Direct Plan - Growth Plan
Nippon India Pharma Fund - Direct Plan - Growth Plan is a Equity mutual fund scheme from Nippon Life India Asset Management Ltd. This fund has been in existence for 13 years, having been launched on 2013-01-01. Nippon India Pharma Fund - Direct Plan - Growth Plan has ₹7875.40 Cr worth of assets under management (AUM) as of Tue Mar 03 2026. The latest Net Asset Value (NAV) of Nippon India Pharma Fund - Direct Plan - Growth Plan as of Mon Mar 02 2026 is ₹574.4547. The fund has an expense ratio of 0.93%, which is medium comparable to most other Equity funds.
Nippon India Pharma Fund - Direct Plan - Growth Plan returns for the last 1 year are 14.55%. Since launch, it has delivered 17.37% average annual returns.
The Nippon India Pharma Fund - Direct Plan - Growth Plan has the majority of its money invested in Healthcare sectors.
Top 5 Holdings of Nippon India Pharma Fund - Direct Plan - Growth Plan.
- Sun Pharmaceuticals Industries Ltd: 12.67%
- Lupin Ltd: 7.88%
- Divi's Laboratories Ltd: 6.54%
- Dr Reddy's Laboratories Ltd: 6.06%
- Cipla Ltd: 5.88%
AMC Information
| Name | Nippon Life India Asset Management Ltd |
|---|---|
| Founding Date | 2013-01-01 |
| customercare@nipponindiaim.in | |
| Phone | 022-6808 7000/18602660111 |
| Website | https://mf.nipponindiaim.com/ |
| Address | Nippon Life India Asset Management Limited,4th Floor, Tower A, Peninsula Business Park,,Ganapatrao Kadam Marg,,Lower Parel (W) |
Tax Implications of Nippon India Pharma Fund - Direct Plan - Growth Plan
| Short Term Gains | 20% + applicable Surcharge + 4% Cess |
|---|---|
| Long Term Gains | 12.5% without indexation + applicable Surcharge + 4% Cess |
Similar Funds from Nippon Life India Asset Management Ltd
Nippon India Aggressive Hybrid Fund - Direct Plan - Growth Option
AllocationAggressive Allocation
3Y CAGR
16.38%
expense ratio
1.07%
fund size
₹4024.55 Cr
Nippon India ELSS Tax Saver Fund Direct Plan - Growth Option
EquityELSS (Tax Savings)
3Y CAGR
18.84%
expense ratio
1.03%
fund size
₹14881.42 Cr
Nippon India Multi Cap Fund - Direct Plan - Growth
EquityMulti-Cap
3Y CAGR
22.44%
expense ratio
0.72%
fund size
₹48808.64 Cr
Nippon India Equity Savings Direct Growth
AllocationEquity Savings
3Y CAGR
10.11%
expense ratio
0.49%
fund size
₹933.24 Cr
Nippon India Equity Savings Growth
AllocationEquity Savings
3Y CAGR
9.06%
expense ratio
1.57%
fund size
₹933.24 Cr
Calculate Your Returns
Estimated Returns in 3 Years (Based on past 3Y returns)
₹0
Total Amount
₹0
